207 related articles for article (PubMed ID: 31525627)
1. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims.
Bruno D; Marc D; Ouarda P; Dominique S; Marc S; Laurène C; Khalil J; Jonathan E; Francis G
Mult Scler Relat Disord; 2019 Nov; 36():101396. PubMed ID: 31525627
[TBL] [Abstract][Full Text] [Related]
2. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
Kim Y; Krause TM; Blum P; Freeman L
Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
[TBL] [Abstract][Full Text] [Related]
3. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
Prescott JD; Factor S; Pill M; Levi GW
J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of highly active relapsing-remitting multiple sclerosis patients in the French national health insurance database.
Vandhuick O; Payet M; Préaud E; Lortet-Tieulent J; Raguideau F; Chevreuil O; van Hille B; Kwiatkowski A
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1135-1144. PubMed ID: 34165377
[TBL] [Abstract][Full Text] [Related]
5. [Cost of multiple sclerosis in France].
Fromont A; Lehanneur MN; Rollot F; Weill A; Clerc L; Bonithon Kopp C; Binquet C; Moreau T
Rev Neurol (Paris); 2014; 170(6-7):432-9. PubMed ID: 24856285
[TBL] [Abstract][Full Text] [Related]
6. [The cost of treatment of multiple sclerosis in Colombia].
Romero M; Arango C; Alvis N; Suarez JC; Duque A
Value Health; 2011; 14(5 Suppl 1):S48-50. PubMed ID: 21839899
[TBL] [Abstract][Full Text] [Related]
7. Cost of multiple sclerosis in the Czech Republic: the COMS study.
Blahova Dusankova J; Kalincik T; Dolezal T; Kobelt G; Havrdova E
Mult Scler; 2012 May; 18(5):662-8. PubMed ID: 21965424
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of multiple sclerosis in the UK, Germany and France.
Murphy N; Confavreux C; Haas J; König N; Roullet E; Sailer M; Swash M; Young C; Mérot JL;
Pharmacoeconomics; 1998 May; 13(5 Pt 2):607-22. PubMed ID: 17165327
[TBL] [Abstract][Full Text] [Related]
9. Costs and quality of life of multiple sclerosis in Switzerland.
Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338
[TBL] [Abstract][Full Text] [Related]
10. Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.
Parisé H; Laliberté F; Lefebvre P; Duh MS; Kim E; Agashivala N; Abouzaid S; Weinstock-Guttman B
J Neurol Sci; 2013 Jul; 330(1-2):71-7. PubMed ID: 23647840
[TBL] [Abstract][Full Text] [Related]
11. Burden of illness of multiple sclerosis: Part I: Cost of illness. The Canadian Burden of Illness Study Group.
Can J Neurol Sci; 1998 Feb; 25(1):23-30. PubMed ID: 9532277
[TBL] [Abstract][Full Text] [Related]
12. New insights into the burden and costs of multiple sclerosis in Europe: Results for France.
Lebrun-Frenay C; Kobelt G; Berg J; Capsa D; Gannedahl M;
Mult Scler; 2017 Aug; 23(2_suppl):65-77. PubMed ID: 28643588
[TBL] [Abstract][Full Text] [Related]
13. Costs and quality of life of multiple sclerosis in Austria.
Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with the healthcare expenditures of patients with multiple sclerosis in urban areas of China estimated by a generalized estimating equation.
Du Y; Min R; Zhang X; Fang P
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):137-144. PubMed ID: 31984811
[No Abstract] [Full Text] [Related]
15. Direct and indirect economic consequences of multiple sclerosis in Ireland.
Fogarty E; Walsh C; McGuigan C; Tubridy N; Barry M
Appl Health Econ Health Policy; 2014 Dec; 12(6):635-45. PubMed ID: 25227118
[TBL] [Abstract][Full Text] [Related]
16. Costs and quality of life for patients with multiple sclerosis in Belgium.
Kobelt G
Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
[TBL] [Abstract][Full Text] [Related]
17. Impact on healthcare resource utilization of multiple sclerosis in Spain.
Sicras-Mainar A; Ruíz-Beato E; Navarro-Artieda R; Maurino J
BMC Health Serv Res; 2017 Dec; 17(1):854. PubMed ID: 29284493
[TBL] [Abstract][Full Text] [Related]
18. Costs and quality of life of patients with multiple sclerosis in Europe.
Kobelt G; Berg J; Lindgren P; Fredrikson S; Jönsson B
J Neurol Neurosurg Psychiatry; 2006 Aug; 77(8):918-26. PubMed ID: 16690691
[TBL] [Abstract][Full Text] [Related]
19. Perspectives in multiple sclerosis health care: special focus on the costs of multiple sclerosis.
Rotstein Z; Hazan R; Barak Y; Achiron A
Autoimmun Rev; 2006 Oct; 5(8):511-6. PubMed ID: 17027884
[TBL] [Abstract][Full Text] [Related]
20. Recent transition of medical cost and relapse rate of multiple sclerosis in Japan based on analysis of a health insurance claims database.
Kawachi I; Okamoto S; Sakamoto M; Ohta H; Nakamura Y; Iwasaki K; Yoshida M; Hiroi S; Ogino M
BMC Neurol; 2019 Dec; 19(1):324. PubMed ID: 31842786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
